Fujimura et al evaluated circulating sCD163 and CXCL5 levels at baseline and day 42 after initial treatment with nivolumab in melanoma patients (154), showing that the sCD163 absolute change rate was significantly increased in patients with irAEs compared to those without irAEs. This evidence concerns the gene CD163 and melanoma.